106 related articles for article (PubMed ID: 11365647)
1. New abacavir data open door to a better treatment paradigm.
AIDS Alert; 1998 Aug; 13(8):85-7. PubMed ID: 11365647
[TBL] [Abstract][Full Text] [Related]
2. New drugs: amprenavir and abacavir.
TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
[TBL] [Abstract][Full Text] [Related]
3. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
[TBL] [Abstract][Full Text] [Related]
5. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
Maggiolo F; Callegaro A; Arici C; Quinzan G; Gregis G; Ripamonti D; Tebaldi A; Goglio A; Suter F
Antivir Ther; 2003 Apr; 8(2):121-6. PubMed ID: 12741624
[TBL] [Abstract][Full Text] [Related]
8. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
9. Abacavir update.
Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
[TBL] [Abstract][Full Text] [Related]
10. Glaxo Wellcome's two new drugs.
Res Initiat Treat Action; 1998 Dec; 4(7):14. PubMed ID: 11366081
[TBL] [Abstract][Full Text] [Related]
11. Preliminary report on 1592.
AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
[TBL] [Abstract][Full Text] [Related]
12. Coming therapies: abacavir.
Staszewski S
Int J Clin Pract Suppl; 1999 Jun; 103():35-8. PubMed ID: 10622042
[TBL] [Abstract][Full Text] [Related]
13. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
[TBL] [Abstract][Full Text] [Related]
14. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
15. The fuss over 1592.
Vazquez E
Posit Aware; 1997; 8(5):26-7. PubMed ID: 11364637
[TBL] [Abstract][Full Text] [Related]
16. Ziagen (abacavir) approved: caution essential.
James JS
AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
[TBL] [Abstract][Full Text] [Related]
17. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Hanna L
BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
[TBL] [Abstract][Full Text] [Related]
18. Antivirals update.
Proj Inf Perspect; 1998 Dec; (26):8-10. PubMed ID: 11366501
[TBL] [Abstract][Full Text] [Related]
19. Abacavir: new preparation. Risks limit the value.
Prescrire Int; 2000 Jun; 9(47):67-9. PubMed ID: 11010740
[TBL] [Abstract][Full Text] [Related]
20. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
